COBENFY™ (xanomeline and trospium chloride) is an oral pill used for the treatment of schizophrenia in adults. See indication and Important Safety Information.

Sep 24, 2024 · Cobenfy (xanomeline and trospium chloride) is a new treatment for schizophrenia used to improve positive and negative symptoms. Cobenfy contains xanomeline, which helps …

Cobenfy (xanomeline-trospium chloride) was approved for the treatment of adults with schizophrenia in 2024. Cobenfy is the first medicine approved for the treatment of …

Jan 6, 2025 · Antipsychotic drugs that target dopamine directly have been given to patients with schizophrenia in the form of pills, liquids, and injections since the 1950s. Cobenfy is the first of …

1 day ago · Cobenfy has shown significant improvement in positive, negative, and cognitive symptoms of schizophrenia, with fewer adverse effects like weight gain and extrapyramidal …

FDA approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.

Recently, Cobenfy, a novel antipsychotic combining xanomeline and trospium chloride, received the United States (US) Food and Drug Administration (FDA) approval, marking a significant …

Apr 7, 2025 · Cobenfy (xanomeline/trospium chloride) is a prescription oral capsule that treats schizophrenia in adults. Learn about dosage, side effects, and more.

14 hours ago · COBENFY is the first schizophrenia therapy with a novel mechanism of action approved in over 70 years [1], offering a fundamentally new approach to treating …

Jan 24, 2025 · Cobenfy (xanomeline and trospium chloride) is a prescription medication used to treat schizophrenia in adults. It works by targeting muscarinic receptors in the brain to help …